EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 20-Jun-2026 16:16 ET (20-Jun-2026 20:16 GMT/UTC)

Study finds no link between newborn upper lip frenulum structure and breastfeeding difficulties

University of Oulu, Finland
Peer-Reviewed Publication

A joint study by the University of Oulu and Oulu University Hospital suggests that a newborn’s upper lip frenulum is unlikely to be a major cause of breastfeeding difficulties.

Journal: JAMA Network Open

COPA Mutations: an unexpected trigger for intestinal tumors

Keio University Global Research Institute
Peer-Reviewed Publication

Small intestinal cancer is a rare and poorly understood disease, partly because the molecular drivers behind it have remained unclear. Now, researchers from Japan have identified mutations in COPA—a gene involved in cellular cargo transport with no prior link to cancer—as an alternative route to small intestine tumorigenesis. Their findings may help explain how these tumors develop and could inform and advance future diagnosis and treatment strategies.

Journal: Nature Genetics
Funder: National Cancer Center Research and Development Fund, Japan Society for the Promotion of Science, Japan Science and Technology Agency

Organ-preserving versus radical resection for ureteral urothelial carcinoma

Science China Press
Peer-Reviewed Publication

A propensity score-matched cohort study compared kidney-sparing surgery with radical nephroureterectomy in patients with ureteral urothelial carcinoma. After matching, radical nephroureterectomy was associated with better overall and cancer-specific survival, especially in selected subgroups. The findings support refined risk stratification and careful patient selection

Journal: Medicine Plus

HKUMed develops novel combination therapy to reduce leukaemia relapse rate, extending window for bone marrow transplants

The University of Hong Kong
Peer-Reviewed Publication

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that significantly improves treatment outcomes and survival in patients with acute myeloid leukaemia (AML) with FLT3 gene mutations. The study found that the combined use of the FLT3 inhibitor Quizartinib and the protein synthesis inhibitor Omacetaxine Mepesuccinate (collectively termed QUIZOM) effectively suppresses the growth of cancer cells and activates the patient’s immune system, achieving a composite complete remission (CRc) rate of about 83% while reducing the risk of relapse.

Journal: Nature Communications

UCLA-led research suggests early heart changes may predict future cancer risk

University of California - Los Angeles Health Sciences
Peer-Reviewed Publication

A new study led by UCLA Health physician-scientists suggests that subtle changes in heart structure and function may signal an increased risk for developing certain cancers years later.

Journal: Journal of the American Heart Association

Embargoed study: Mesothelioma cases and deaths rise despite decades of asbestos regulation

University of Miami Miller School of Medicine
Peer-Reviewed Publication

Mesothelioma deaths and diagnoses are still rising in the U.S. despite decades of asbestos regulation, according to a Sylvester study. Survival has improved little, and this largely preventable cancer continues to disproportionately affect women and high-risk states linked to shipbuilding, mining and asbestos exposure.

Journal: JCO Global Oncology

UCLA researchers awarded NIH grant to improve detection and treatment of glioblastoma

University of California - Los Angeles Health Sciences
Grant and Award Announcement

Researchers from the UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million grant from the National Institutes of Health to develop advanced imaging and surgical strategies aimed at improving outcomes for patients with glioblastoma, a fast-growing and aggressive brain tumor.

Alliance announces FDA Acceptance of Supplemental Biologics License Application supported by results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer

Alliance for Clinical Trials in Oncology
Business Announcement

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq^®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The application is supported by findings from the phase III Alliance ATOMIC (A021502) trial, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, and the German group Arbeitsgemeinschaft Internistische Onkologie (AIO). The study demonstrated that patients experienced significantly improved outcomes when atezolizumab was added to standard chemotherapy following surgery.

Ludwig Lausanne’s Johanna Joyce begins presidency of the European Association for Cancer Research

Ludwig Institute for Cancer Research
Business Announcement

Our congratulations to Ludwig Lausanne’s Johanna Joyce, who began her two-year term today as President of the European Association for Cancer Research (EACR), a global community of scientists and clinicians dedicated to advancing the scientific understanding of cancer and its application to improve patient care.

Funder: European Association for Cancer Research

CPRIT invests over $11 million to fuel UH breakthroughs in cancer research

University of Houston
Grant and Award Announcement

Two new grants from the Cancer Prevention and Research Institute of Texas bring the total of active CPRIT grants at UH to $11.1 million, and both are meant to develop new strategies to fight lung cancer.

6
7
8
9
10